Supernus Pharmaceuticals (SUPN) Downgraded by Zacks Investment Research

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a report released on Thursday.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Other equities analysts also recently issued research reports about the stock. BidaskClub raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, September 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $56.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, September 14th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $46.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, July 25th. Finally, Jefferies Financial Group lifted their price target on shares of Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company. Supernus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $54.67.

Shares of NASDAQ:SUPN opened at $47.43 on Thursday. The company has a current ratio of 2.74, a quick ratio of 2.54 and a debt-to-equity ratio of 0.82. Supernus Pharmaceuticals has a 1-year low of $33.30 and a 1-year high of $61.25. The company has a market cap of $2.63 billion, a price-to-earnings ratio of 37.64 and a beta of 0.79.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.14. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. The business had revenue of $99.54 million for the quarter, compared to the consensus estimate of $101.01 million. On average, equities research analysts predict that Supernus Pharmaceuticals will post 1.97 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Supernus Pharmaceuticals by 8.7% during the second quarter. BlackRock Inc. now owns 7,690,669 shares of the specialty pharmaceutical company’s stock valued at $460,287,000 after buying an additional 618,722 shares during the last quarter. Summit Trail Advisors LLC increased its position in Supernus Pharmaceuticals by 4,144.2% in the first quarter. Summit Trail Advisors LLC now owns 1,617,365 shares of the specialty pharmaceutical company’s stock worth $1,617,000 after purchasing an additional 1,579,257 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Supernus Pharmaceuticals by 0.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,403,994 shares of the specialty pharmaceutical company’s stock worth $64,303,000 after purchasing an additional 4,844 shares during the last quarter. Wells Fargo & Company MN increased its position in Supernus Pharmaceuticals by 6.8% in the second quarter. Wells Fargo & Company MN now owns 957,210 shares of the specialty pharmaceutical company’s stock worth $57,290,000 after purchasing an additional 61,100 shares during the last quarter. Finally, FMR LLC increased its position in Supernus Pharmaceuticals by 1,909.6% in the second quarter. FMR LLC now owns 941,300 shares of the specialty pharmaceutical company’s stock worth $56,337,000 after purchasing an additional 894,459 shares during the last quarter. Hedge funds and other institutional investors own 97.45% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Recommended Story: What is a Call Option?

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply